Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)

NCT03841110 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT03841110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03841110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)
Lead sponsor
Fate Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
February 15, 2019
Completion date
November 15, 2022
Enrollment
37 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, cervical cancer, colorectal cancer, egfr positive solid tumor, gastric cancer, head and neck cancer, hepatocellular carcinoma, her2-positive breast cancer, lymphoma, melanoma, merkel cell carcinoma, microsatellite instability, nsclc, pancreas cancer, renal cell carcinoma, small cell lung cancer, squamous cell carcinoma, urothelial carcinoma